Market Access

Supporting health plan clinical preparation and financial modeling.

Using market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.

Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?

Webinar Date/Time: Tuesday, Dec 6, 2022, 11am PT | 2pm ET

Webinar Date/Time: Wednesday, November 30, 2022, 1 pm EDT

Life sciences professionals will need to keep up with market demand for biologics and biosimilars.

Commercial Health Insurance may bring more opportunities for market access in China.

Different paths to formulary decision-making.

FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.

A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Gaps remain in the pre-approval information process leave payers without all of the information they need to make the proper decisions.

The BCG Market Access Roundtable outlines the new and advanced access competencies required to enable functional operationalization and delivery of this critical role in biopharma—today a key strategic partner in achieving overall business goals.

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Using data visualizations to improve access to payers.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Reversing non-formulary status will usually require new data.

Kalidas spoke with Pharm Exec about her efforts to bring equity to underserved patients and their communities through Bayer’s Oncology Sustainability Initiative.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.

Tackling the subjective limits of value proposition.

Assessing the road ahead for Chinese biotech.

Payers not looking to favor one product.